Biotech Values

[onco_investor]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.

Edits: Added ONCY who have now started a Phase 3 in refractory SCC Head & Neck Cancer with a FDA SPA in hand. ONCY is also more than midway through a closely watched Phase 2 trial for first line kras+ NSCLC lung cancer. Preliminary data in this Phase 2 trial is due in Q3-2010. ONCY may partner or raise funds after this data is released as the company is currently only funded to complete and analyze the first-look portion of the Phase 3 at this time.

 
  Company  Product     Phase   Indication (notes)     
  =======  =======     =====   ==================     
  ARNA     Lorcaserin  NDA     Obesity     
  ARYX     Budiodarone 2B      Atrial Fibrillation   
  ARYX     Tecarfarin  3       VTE prevention (failed initial ph-3)   
  BPAX     Libigel     3       Female Sexual Desire Disorder     
  DYAX     Kalbitor    US app  acute HAE (seeking ex-US partner)     
  HNAB     Marqibo     2B      ALL (ENZN failed acc. approval in NHL)  
  JAV      Dyloject    NDA     Post-op pain (approved in UK)     
  JAV      Ketamine    3       Acute pain     
  ONCY     Reolysin    3       SCC Head & Neck cancer (ph-3 SPA) 	 
  OREX     Contrave    NDA     Obesity     
  OXGN     Zybrestat   3       Anaplastic thyroid cancer     
  MNKD     Afrezza     BLA     Diabetes (CRL rec’d 3/15/10)     
  Pharming Rhucin      BLA     HAE (CHMP decision expctd Jun 2010)     
  SOMX     Silenor     apprvd  Insomnia (low dose of generic doxepin)     
  SVNT     Krystexxa   BLA     Gout (response to CRL submtd 3/30/10)     
  VVUS     Qnexa       NDA     Obesity 
 

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.